Offerings Archives - Page 12 of 166

1 minute read

NRx Pharmaceuticals, Inc. Announces Pricing Of $2M Underwritten Public Offering Of Common Stock At A Public Offering Price Of $3.30 Per Share

April 18, 8:35 AM

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of shares of its common stock

NRXP

1 minute read

Biohaven Announces $200M Public Offering Of Common Shares

By Benzinga Newsdesk

April 17, 4:15 PM

Biohaven Ltd. (NYSE:BHVN), a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology,

BHVN

1 minute read

ICZOOM Announces Cancellation Of Proposed Public Offering; Cancellation Due To Current Market Pricing Not Conducive For Offering That Would Be In Best Interests Of Co Or Its Shareholders

By Benzinga Newsdesk

April 17, 10:56 AM

ICZOOM Group Inc. (NASDAQ:IZM) (the "Company" or "ICZOOM"), announced today that it voluntarily requested a withdrawal of a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (File

IZM

2 minute read

On April 16, 2024, Trio Petroleum Corp. Entered Into A SPA With An Institutional Investor In The Amount Of $360,000 Resulting In Net Proceeds To The Company, After Offering Expenses, Of $310,000 For 750K Shares Of Common Stock

By Benzinga Newsdesk

April 17, 10:11 AM

On April 16, 2024, Trio Petroleum Corp., a Delaware corporation (the "Company"), entered into a securities purchase agreement (the "SPA") with an institutional investor (the "Investor"). Pursuant to the terms and

TPET

2 minute read

Longeveron Announces Exercise Of Warrants For $6.2M Gross Proceeds

By Benzinga Newsdesk

April 17, 8:16 AM

Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left

LGVN

2 minute read

BranchOut Food Strengthens Financial Position With Sale Of $225K Senior Secured Promissory Notes And Warrants To Purchase An Aggregate Of 56,250 Shares Of The Company’s Common Stock. Each Warrant Is Exercisable For A Ten-year Period At An Exercise Pric…

By Benzinga Newsdesk

April 17, 8:11 AM

BranchOut Food Inc. (NASDAQ:BOF), a food technology company and maker of dehydrated fruit and vegetable-based products, today announced that it has completed the sale of $225,000 of Senior Secured Promissory Notes

BOF

1 minute read

Intra-Cellular Therapies Announces $500M Proposed Public Offering Of Common Stock

By Benzinga Newsdesk

April 16, 4:13 PM

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) ("Intra-Cellular Therapies"), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today

ITCI

2 minute read

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

By Vandana Singh

April 16, 1:32 PM

Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show potential for treatment with a differentiated safety profile.

CGEM